Arrowstreet Capital Limited Partnership Increases Stock Position in Genmab A/S Sponsored ADR $GMAB

Arrowstreet Capital Limited Partnership lifted its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 152.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,454,378 shares of the company’s stock after buying an additional 2,084,966 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Genmab A/S were worth $71,367,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Level Four Advisory Services LLC grew its holdings in Genmab A/S by 24.8% during the second quarter. Level Four Advisory Services LLC now owns 64,925 shares of the company’s stock worth $1,341,000 after acquiring an additional 12,888 shares during the period. Capital Fund Management S.A. boosted its position in shares of Genmab A/S by 110.7% during the 2nd quarter. Capital Fund Management S.A. now owns 226,584 shares of the company’s stock worth $4,681,000 after purchasing an additional 119,061 shares in the last quarter. AlphaCore Capital LLC acquired a new position in shares of Genmab A/S during the 2nd quarter worth $44,000. Brandywine Global Investment Management LLC increased its holdings in shares of Genmab A/S by 1.6% in the 2nd quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock valued at $36,047,000 after purchasing an additional 27,372 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Genmab A/S by 17.0% in the second quarter. JPMorgan Chase & Co. now owns 933,309 shares of the company’s stock valued at $19,282,000 after purchasing an additional 135,814 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on GMAB shares. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Johnson Rice restated a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Wall Street Zen raised Genmab A/S from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. Truist Financial reiterated a “buy” rating and set a $48.00 target price (down from $49.00) on shares of Genmab A/S in a research report on Thursday, November 6th. Finally, HC Wainwright raised their price target on Genmab A/S from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $39.75.

Genmab A/S Trading Up 1.1%

Genmab A/S stock opened at $32.02 on Friday. The stock has a fifty day moving average price of $30.78 and a 200 day moving average price of $25.83. Genmab A/S Sponsored ADR has a 52 week low of $17.24 and a 52 week high of $33.65. The firm has a market capitalization of $20.57 billion, a P/E ratio of 13.63, a PEG ratio of 1.65 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating the consensus estimate of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. As a group, equities analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.